We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-16.07%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.14B
AUM Growth
-$212M
Cap. Flow
+$85.4M
Cap. Flow %
7.49%
Top 10 Hldgs %
46.56%
Holding
206
New
51
Increased
51
Reduced
18
Closed
36

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$27.8M
2
HUM icon
Humana
HUM
+$19.1M
3
XLRN
Acceleron Pharma
XLRN
+$15.3M
4
QTNT
Quotient Limited Ordinary Shares
QTNT
+$13.2M
5
MDVN
MEDIVATION, INC.
MDVN
+$12.3M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$68.4M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$12.9M
3
BAX icon
Baxter International
BAX
+$10.1M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$8.54M
5
NVRO
NEVRO CORP.
NVRO
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.87%
2 Consumer Staples 0.6%
3 Consumer Discretionary 0.11%
4 Industrials 0.04%
5 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARO
126
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$491K 0.04%
3,429
+1,936
+130% +$275K
GNVC
127
DELISTED
GenVec, Inc.
GNVC
$489K 0.04%
60,664
-920
-1% -$6.17K
SYNH
128
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$488K 0.04%
+11,846
New +$488K
CAH icon
129
Cardinal Health
CAH
$55.5B
$487K 0.04%
+5,947
New +$484K
AFAM
130
DELISTED
Almost Family Inc
AFAM
$487K 0.04%
13,075
+8,186
+167% +$306K
IQV icon
131
IQVIA
IQV
$43B
$485K 0.04%
7,447
+4,749
+176% +$300K
CRL icon
132
Charles River Laboratories
CRL
$14.2B
$474K 0.04%
6,244
+2,834
+83% +$210K
MACK
133
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$419K 0.04%
6,355
– –
PMC
134
DELISTED
PharMerica Corporation
PMC
$372K 0.03%
16,841
+10,041
+148% +$267K
GLMD icon
135
Galmed Pharmaceuticals
GLMD
$4.42M
$369K 0.03%
52
– –
STML
136
DELISTED
Stemline Therapeutics, Inc.
STML
$366K 0.03%
78,603
– –
GRCE
137
Grace Therapeutics
GRCE
$45.4M
$360K 0.03%
4,928
– –
SPY icon
138
State Street SPDR S&P 500 ETF Trust
SPY
$822B
$329K 0.03%
+1,600
New +$312K
ARMP icon
139
Armata Pharmaceuticals
ARMP
$202M
$315K 0.03%
571
+37
+7% +$19K
CNC icon
140
Centene
CNC
$33.2B
$305K 0.03%
9,896
+4,710
+91% +$141K
TRIL
141
DELISTED
Trillium Therapeutics Inc.
TRIL
$278K 0.02%
30,000
– –
APYX icon
142
Apyx Medical
APYX
$130M
$272K 0.02%
162,700
– –
IMUX icon
143
Immunic
IMUX
$225M
$271K 0.02%
+75
New +$261K
DRNA
144
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$268K 0.02%
50,000
– –
GTS
145
DELISTED
Triple-S Management Corporation
GTS
$264K 0.02%
11,147
– –
RACE icon
146
Ferrari
RACE
$73.1B
$259K 0.02%
+6,200
New +$250K
TNDM icon
147
Tandem Diabetes Care
TNDM
$1.48B
$217K 0.02%
2,500
– –
ELGX
148
DELISTED
Endologix Inc
ELGX
$209K 0.02%
2,500
-27,500
-92% -$2.27M
AKAO
149
DELISTED
Achaogen Inc
AKAO
$166K 0.01%
60,000
– –
MNK
150
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$164K 0.01%
+2,673
New +$171K
4 5
6
7 8

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q1 2016 Portfolio in Review

As of Q1 2016, Perceptive Advisors held 206 positions worth $1.14B, down 16% from $1.35B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $85.4M of net new capital in Q1 2016, opening 51 new positions and adding to 51 existing holdings. Its largest new stake was Humana: 110,000 shares worth $20.1M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $12.9M trimmed.

  • Perceptive Advisors's largest Q1 2016 buy was Humana: 110,000 shares worth $20.1M.
  • Perceptive Advisors added most to Sarepta Therapeutics in Q1 2016, an estimated $27.8M increase.
  • Perceptive Advisors's biggest Q1 2016 reduction was Teva Pharmaceuticals, cutting an estimated $12.9M.
  • Perceptive Advisors fully exited DYAX CORPORATION in Q1 2016, selling an estimated $68.4M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.14B portfolio in Q1 2016.
  • Perceptive Advisors opened 51 new positions and closed 36 in Q1 2016.
  • Perceptive Advisors's portfolio value fell 16% quarter-over-quarter to $1.14B.

Based on Perceptive Advisors's 13F filing for Q1 2016, filed 16 May 2016.